162 related articles for article (PubMed ID: 37880078)
1. The effect of acromegaly on thyroid disease.
Mo C; Zhong L
Endocr J; 2023 Nov; 70(11):1051-1060. PubMed ID: 37880078
[TBL] [Abstract][Full Text] [Related]
2. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
4. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.
Gasperi M; Martino E; Manetti L; Arosio M; Porretti S; Faglia G; Mariotti S; Colao AM; Lombardi G; Baldelli R; Camanni F; Liuzzi A;
J Endocrinol Invest; 2002 Mar; 25(3):240-5. PubMed ID: 11936466
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
7. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up.
Cannavò S; Squadrito S; Finocchiaro MD; Curtò L; Almoto B; Vieni A; Trimarchi F
Horm Metab Res; 2000 May; 32(5):190-5. PubMed ID: 10871160
[TBL] [Abstract][Full Text] [Related]
8. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
12. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
13. Thyroid-related ophthalmopathy development in concurrence with growth hormone administration.
Iwata S; Tsumura K; Ashida K; Tokubuchi I; Demiya M; Kitamura M; Ohshima H; Yano M; Nagayama A; Yasuda J; Tsuruta M; Motomura S; Yoshida S; Nomura M
BMC Endocr Disord; 2021 Aug; 21(1):168. PubMed ID: 34412613
[TBL] [Abstract][Full Text] [Related]
14. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
15. DECREASE IN ACROMEGALY-ASSOCIATED THYROID ENLARGEMENT AFTER NORMALIZATION OF IGF-1 LEVELS: A PROSPECTIVE OBSERVATION AND IN VITRO STUDY.
Chen Z; Jiang X; Feng Y; Li X; Chen D; Mao Z; He D; Zhu Y; Wang H
Endocr Pract; 2020 Apr; 26(4):369-377. PubMed ID: 31859554
[No Abstract] [Full Text] [Related]
16. MiR-143 Targets IGF-1R to Suppress Autoimmunity in Thyroid-Associated Ophthalmopathy.
Tang W; Lv Q; Huang X; Li Y; Zou J; Zheng J; Sun L; Bao Y; Chen H; Li T; Zhang B; Xue S; Song Y; Zhang X; Chen X; Cai J; Shi Y
J Inflamm Res; 2022; 15():1543-1554. PubMed ID: 35256853
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
[TBL] [Abstract][Full Text] [Related]
18. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
Neumann S; Krieger CC; Gershengorn MC
Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
[TBL] [Abstract][Full Text] [Related]
19. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland.
Kasagi K; Shimatsu A; Miyamoto S; Misaki T; Sakahara H; Konishi J
Thyroid; 1999 Aug; 9(8):791-6. PubMed ID: 10482372
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of differentiated thyroid carcinoma in acromegaly.
Tita P; Ambrosio MR; Scollo C; Carta A; Gangemi P; Bondanelli M; Vigneri R; degli Uberti EC; Pezzino V
Clin Endocrinol (Oxf); 2005 Aug; 63(2):161-7. PubMed ID: 16060909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
